Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

344
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
344
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

715
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
715
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

576
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
576
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.

European review for medical and pharmacological sciences·2019
Same author

Short hairpin ribonucleic acid constructs targeting insulin-like growth factor binding protein-3 rehabilitated dyslipidaemia in diabetic rats.

Andrologia·2015
Same author

[Vasomotor rhinitis following endoscopic sinus surgery: 5 cases report].

Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology·2003
Same author

[Guided tissue regeneration with Biomesh membrane for Class II furcation defects].

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology·2003
Same author

Comparative study on the immunogenicity between Hsp70 DNA vaccine and Hsp65 DNA vaccine in human Mycobacterium tuberculosis.

Journal of Tongji Medical University = Tong ji yi ke da xue xue bao·2003
Same author

[Study on the effect of several antioxidants on the stability of oils].

Wei sheng yan jiu = Journal of hygiene research·2003

Related Experiment Video

Updated: Mar 27, 2026

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.3K

Decrease of the insulin-like growth factor-1 bioavailability in spontaneously hypertensive rats with erectile

Z-Y Zhou1, S-P Cheng1, H Huang1

  • 1Department of Urology, First Affiliated Hospital of Yangtze University, Jingzhou, HuBei, China.

Andrologia
|January 15, 2016
PubMed
Summary
This summary is machine-generated.

Low insulin-like growth factor-1 (IGF-1) levels are linked to erectile dysfunction in spontaneously hypertensive rats. Reduced IGF-1 bioavailability and cyclic guanosine monophosphate concentrations were observed in these rats.

Keywords:
Erectile dysfunctioninsulin-like growth factor-1spontaneously hypertensive rats

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

9.3K

Related Experiment Videos

Last Updated: Mar 27, 2026

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.3K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

9.3K

Area of Science:

  • Endocrinology
  • Urology
  • Cardiovascular Research

Background:

  • Erectile dysfunction (ED) is a common complication in spontaneously hypertensive rats.
  • Insulin-like growth factor-1 (IGF-1) plays a crucial role in various physiological processes, including vascular function.

Purpose of the Study:

  • To investigate the role of insulin-like growth factor-1 (IGF-1) in the pathophysiology of erectile dysfunction in spontaneously hypertensive rats.
  • To assess the correlation between IGF-1 levels, erectile function, and cyclic guanosine monophosphate (cGMP) concentrations.

Main Methods:

  • Quantitative real-time PCR and Western blot were used to measure IGF-1 mRNA and protein levels.
  • Intracavernous pressure was measured to evaluate erectile function.
  • Enzyme-linked immunosorbent assay (ELISA) was employed to detect cavernous cyclic guanosine monophosphate (cGMP) concentrations.

Main Results:

  • Spontaneously hypertensive rats exhibited significantly decreased cavernosal pressure compared to control rats.
  • Both IGF-1 bioavailability (mRNA and protein) and cavernous cGMP concentrations were significantly reduced in hypertensive rats.
  • Propranolol treatment in hypertensive rats also led to decreased cavernosal pressure, IGF-1 bioavailability, and cGMP levels.

Conclusions:

  • A significant decrease in cavernous IGF-1 bioavailability is strongly associated with erectile dysfunction in spontaneously hypertensive rats.
  • Reduced IGF-1 levels may be a key contributing factor to the development of erectile dysfunction in this hypertensive model.
  • These findings highlight the potential therapeutic relevance of targeting IGF-1 pathways for erectile dysfunction in hypertension.